U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
Go back to U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review| Merck & Co. (NYSE: MRK) | Delayed: 133.59 +0.67 (0.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $132.92 | 52 Week High | $65.46 | |||
| Open | $133.86 | 52 Week Low | $47.97 | |||
| Day High | $134.31 | P/E | 90.88 | |||
| Day Low | $133.06 | EPS | $1.47 | |||
| Volume | 395,783 | |||||
